Literature DB >> 33094214

COVID-19 Pandemic and Neurological Disease: A Critical Review of the Existing Literature.

Shervin Assari1.   

Abstract

Most of what we know about the coronavirus disease 2019 (COVID-19) is limited to what we know about severe acute respiratory syndrome (SARS) and COVID-19's epidemiology, fatality, and acute care. However, infection with COVID-19 may also involve the central nervous system (CNS), which may or may not be due to a multi-organ injury. Our aim in this paper is to briefly summarize the main aspects of the growing literature on neurological manifestations of the COVID-19 infection. As such, after mentioning some general background on the economic and medical implications of the pandemic on individuals, the healthcare system, and the society, we summarize some common aspects of the published literature on neurological manifestations of the COVID-19 infection. We also highlight the existing gaps in the literature, which requires additional work. The most common neurological manifestation of COVID-19 infection is an olfactory deficit. However, it is still unknown if it is inflammatory or degenerative in nature. Still, the incidence of neurological complications, and also their mechanisms and treatments are unknown. This literature is predominantly composed of opinions and reviews rather than original articles, so the patients' data are not used for a majority of the studies. Multi-center studies that not only conduct chest CT or MRI but also brain CT or MRI are needed. Randomized trials are still required on the management of acute and chronic neurological conditions due to COVID-19 infection. Cohort studies may also determine the natural history of the conditions and factors that are prognostic. Furthermore, while disparities in COVID-19 infections are known, inequalities in neurological manifestations are unknown. Besides this, the efficacy of specific treatments on CNS involvement is still unknown. We will discuss the health care needs of patients with chronic neurological conditions. We Included a few recommendations for practice and further research at the end of this paper.

Entities:  

Keywords:  Brain; Central Nervous System (CNS); Coronavirus Disease 2019 (COVID-19); Neurological Disease; Neurology; Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Year:  2020        PMID: 33094214

Source DB:  PubMed          Journal:  Hosp Pract Res        ISSN: 2476-3918


  6 in total

1.  Suspected Recurrence of Cranial Neuralgia Following Infection With SARS-CoV-2: A Case Report.

Authors:  Leslie Fuller; Jillian Moehle; Angela Hardin
Journal:  Integr Med (Encinitas)       Date:  2022-05

Review 2.  Cellular mechanisms underlying neurological/neuropsychiatric manifestations of COVID-19.

Authors:  Brittany Bodnar; Kena Patel; Wenzhe Ho; Jin Jun Luo; Wenhui Hu
Journal:  J Med Virol       Date:  2020-12-23       Impact factor: 2.327

Review 3.  Insight into prognostics, diagnostics, and management strategies for SARS CoV-2.

Authors:  Umay Amara; Sidra Rashid; Khalid Mahmood; Mian Hasnain Nawaz; Akhtar Hayat; Maria Hassan
Journal:  RSC Adv       Date:  2022-03-11       Impact factor: 3.361

4.  Mitigating COVID-19 Risk and Vaccine Hesitancy Among Underserved African American and Latinx Individuals with Mental Illness Through Mental Health Therapist-Facilitated Discussions.

Authors:  Angela L Venegas-Murillo; Mohsen Bazargan; Stephen Grace; Sharon Cobb; Roberto Vargas; Shronda Givens; Sheila Li-Sarain; Carissa Delgado; Jeffry Villatoro; Asia Goodall; Rylan Tesimale; Sylvia Ramirez; Monica Brown; John Uyanne; Shervin Assari
Journal:  J Racial Ethn Health Disparities       Date:  2022-05-09

5.  Effects of Varying Glucose Concentrations on ACE2's Hypothalamic Expression and Its Potential Relation to COVID-19-Associated Neurological Dysfunction.

Authors:  Ankita Srivastava; Bashair M Mussa
Journal:  Int J Mol Sci       Date:  2022-08-25       Impact factor: 6.208

Review 6.  COVID-19 and Neurological Impairment: Hypothalamic Circuits and Beyond.

Authors:  Bashair M Mussa; Ankita Srivastava; Anthony J M Verberne
Journal:  Viruses       Date:  2021-03-17       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.